Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC.GLYC · Entity 5255 | SVP & Chief Commercial Officer | January 12, 2024 | January 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRESCENT BIOPHARMA, INC.
Report date January 12, 2024 · Filed January 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.11 · Expires 2034-01-11 | Direct | 250,000 |
Reported balance
After 2024-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-12 · Grant · Acquired 250,000 · Balance 250,000 F1: 25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2024 Filed Jan 17, 2024 21:05 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001209191-24-001742 · doc4.xml · derivative · entry 1 Johnson Bruce S · CIK 0001971197 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2034-01-11 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date. Read SEC document |
| May 08, 2023 Filed May 9, 2023 21:00 UTC | CRESCENT BIOPHARMA, INC. GLYC · Entity 5255 | PurchaseCommon Stock | 13,500 | $1.57 | $21,195.00 |
DisclosureSEC source: 0001209191-23-028305 · doc4.xml · nonDerivative · entry 1 Johnson Bruce S · CIK 0001971197 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,980 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.